Federal Register Notice: FDA is making available a draft guidance, Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies. The draft guidance is intended to assist the pharmaceutical industry and other investigators engaged in new drug development in evaluating how variations in the human genome could affect the clinical pharmacology properties and clinical responses of drugs. To download this guidance, click here. To view this notice, click here.